Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients.

Published

Journal Article

BACKGROUND: Although cryosurgery has been proved to be an effective treatment to extend the survival time of unresectable liver cancer patients and improve their quality of life, few surgeons actually treat unresectable pancreatic cancer with this method because of its safety risks. This study aims to evaluate the safety and efficacy of cryosurgical ablation in the treatment for unresectable pancreatic cancer. METHODS: A retrospective study was conducted on 142 patients who underwent palliative bypass with cryoablation (PBC group: 68) or without cryoablation (PB group: 74) for unresectable pancreatic cancer from 1995 to 2002. The morbidity and 5 year survival rates of the two groups were compared. Carbohydrate antigen 19-9 (CA19-9) level and tumour size were evaluated in PBC group. RESULTS: There was no significant difference in the rate of overall complications between the two groups (p=0.809), except for a higher delayed gastric emptying rate observed in the PBC group (36.8% vs 16.2%, p=0.005). In the PBC group, the median preoperative CA19-9 concentration decreased from 690 U/ml to 56 U/ml (p=0.000). CT scan results of 55 patients indicated that tumour mass shrinkage occurred in 36 of them, from 4.3 cm to 2.4 cm (pre-ablation to 3 months after ablation). Kaplan-Meier analysis showed no significant difference in 5 year survival rates between the two groups (p=0.124). CONCLUSIONS: Cryosurgery combined with palliative bypass surgery can be considered a safe and effective treatment for unresectable pancreatic cancer. Though this technique remains only palliative, it may be further employed to improve advanced stage pancreatic cancer.

Full Text

Cited Authors

  • Li, J; Chen, X; Yang, H; Wang, X; Yuan, D; Zeng, Y; Wen, T; Yan, L; Li, B

Published Date

  • February 2011

Published In

Volume / Issue

  • 87 / 1024

Start / End Page

  • 89 - 95

PubMed ID

  • 21131612

Pubmed Central ID

  • 21131612

Electronic International Standard Serial Number (EISSN)

  • 1469-0756

International Standard Serial Number (ISSN)

  • 0032-5473

Digital Object Identifier (DOI)

  • 10.1136/pgmj.2010.098350

Language

  • eng